Biogen stock is trading -10.16% below its average target price of $170.72 after marking a 9.5% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $118.0 to $260.0 per share.
Biogen's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.5%. The stock's short ratio is 3.35. The company's insiders own 0.15% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 92.6%. In conclusion, we believe there is mixed market sentiment regarding Biogen.
Institutions Invested in Biogen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 12% | 17,290,651 | $2,652,040,134 |
| 2025-06-30 | Primecap Management Company | 11% | 15,802,122 | $2,423,729,549 |
| 2025-06-30 | Blackrock Inc. | 9% | 13,555,466 | $2,079,137,441 |
| 2025-06-30 | State Street Corporation | 5% | 7,468,807 | $1,145,565,654 |
| 2025-06-30 | Wellington Management Group, LLP | 3% | 4,798,420 | $735,981,683 |
| 2025-06-30 | Geode Capital Management, LLC | 3% | 3,918,150 | $600,965,866 |
| 2025-06-30 | Point72 Asset Management, L.P. | 3% | 3,831,727 | $587,710,305 |
| 2025-06-30 | Invesco Ltd. | 2% | 2,320,126 | $355,860,937 |
| 2025-06-30 | NORGES BANK | 2% | 2,264,177 | $347,279,479 |
| 2025-06-30 | Morgan Stanley | 1% | 1,956,210 | $300,043,499 |
